Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2039146 | 0.86 | ALDH1A1 (0.60) | L3MBTL1TSHRLMNAMAPTPOLB | |
| SCHEMBL31429438 | 0.83 | NR4A2 (0.76) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| SCHEMBL2039380 | 0.82 | LMNA (0.54) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| SCHEMBL2036426 | 0.82 | LMNA (0.54) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| SCHEMBL2038601 | 0.82 | NR4A2 (0.47) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| SCHEMBL6984456 | 0.81 | NR4A2 (0.78) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| SCHEMBL1855462 | 0.81 | NR4A2 (1.00) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| SCHEMBL2036700 | 0.81 | PRPS1 (0.53) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| Fluoride SCHEMBL28025004 | 0.80 | NR4A2 (0.76) | L3MBTL1TSHRNR4A2LMNAMAPT | |
| SCHEMBL2042864 | 0.80 | NR4A2 (0.71) | L3MBTL1TSHRNR4A2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102770425-A | Indolyl-piperidinylbenzylamines as beta-tryptase inhibitors | SANOFI SA | 2012-11-07 | — | — | CN | disclosed |
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | L3MBTL1 4194/4885TSHR 1421/4885NR4A2 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.